WO2015019253A3 - Vaccin génétique anti-virus de la dengue à base d'ectodomaines de protéines d'enveloppe - Google Patents

Vaccin génétique anti-virus de la dengue à base d'ectodomaines de protéines d'enveloppe Download PDF

Info

Publication number
WO2015019253A3
WO2015019253A3 PCT/IB2014/063588 IB2014063588W WO2015019253A3 WO 2015019253 A3 WO2015019253 A3 WO 2015019253A3 IB 2014063588 W IB2014063588 W IB 2014063588W WO 2015019253 A3 WO2015019253 A3 WO 2015019253A3
Authority
WO
WIPO (PCT)
Prior art keywords
dengue virus
envelope protein
genetic vaccine
vaccine based
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2014/063588
Other languages
English (en)
Other versions
WO2015019253A2 (fr
Inventor
Oscar Burrone
Marco Bestagno
Monica POGGIANELLA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Centre for Genetic Engineering and Biotechnology
Original Assignee
International Centre for Genetic Engineering and Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Centre for Genetic Engineering and Biotechnology filed Critical International Centre for Genetic Engineering and Biotechnology
Publication of WO2015019253A2 publication Critical patent/WO2015019253A2/fr
Publication of WO2015019253A3 publication Critical patent/WO2015019253A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un vaccin génétique pour le virus de la dengue de tous les sérotypes ou pour tout virus appartenant au genre Flavivirus. Ledit vaccin est basé sur les ectodomaines de protéine E d'enveloppe, plus particulièrement sur le domaine DIII du virus de la dengue ou d'autres Flavivirus. La présente invention concerne une construction génétique codant pour une protéine de fusion dans laquelle ledit domaine de la protéine E d'enveloppe est fusionné à un domaine carboxy-terminal provenant de la région constante d'une immunoglobuline. L'utilisation de ladite construction permet une sécrétion efficace de la protéine de fusion à partir des cellules et par conséquent pour une réponse élevée en anticorps.
PCT/IB2014/063588 2013-08-05 2014-07-31 Vaccin génétique anti-virus de la dengue à base d'ectodomaines de protéines d'enveloppe Ceased WO2015019253A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000458A ITRM20130458A1 (it) 2013-08-05 2013-08-05 Vaccino genetico anti-dengue virus basato sugli ectodomini della proteina envelope
ITRM2013A000458 2013-08-05

Publications (2)

Publication Number Publication Date
WO2015019253A2 WO2015019253A2 (fr) 2015-02-12
WO2015019253A3 true WO2015019253A3 (fr) 2015-05-28

Family

ID=49304201

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/063588 Ceased WO2015019253A2 (fr) 2013-08-05 2014-07-31 Vaccin génétique anti-virus de la dengue à base d'ectodomaines de protéines d'enveloppe

Country Status (2)

Country Link
IT (1) ITRM20130458A1 (fr)
WO (1) WO2015019253A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3003886A1 (fr) * 2015-11-06 2017-05-11 University Of South Alabama Nouvelle plateforme de vaccins a adn
CA3040123A1 (fr) * 2016-10-11 2018-04-19 University Of Miami Vecteurs et cellules de vaccin pour immunite contre le virus zika
CN108503696B (zh) * 2017-02-27 2023-05-12 中国科学院上海巴斯德研究所 一种酵母细胞表达的寨卡病毒亚单位疫苗
US20220289796A1 (en) * 2019-08-06 2022-09-15 The University Of North Carolina At Chapel Hill Methods and compositions for stabilized recombinant flavivirus e protein dimers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234951A1 (en) * 2001-07-16 2004-11-25 Lisset Hermida Cruz Chimeric chains that coding for proteins that induce effects directed against viruses
WO2009099716A1 (fr) * 2008-01-11 2009-08-13 Vgx Pharmaceuticals, Inc. Nouveaux vaccins contre plusieurs sous-types du virus de la dengue
WO2011115583A1 (fr) * 2010-03-19 2011-09-22 National University Of Singapore Nouvelle plate-forme d'identification d'antigènes de vaccins par particule semblable à un rétrovirus (vlp)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455509B1 (en) 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
WO2007034507A2 (fr) 2005-09-20 2007-03-29 International Centre For Genetic Engineering And Biotechnology Proteine de recombinaison chimerique tetravalente basee sur le domaine iii specifique de la dengue
US7981431B2 (en) 2007-06-08 2011-07-19 National Health Research Institutes Consensus dengue virus envelope protein domain III polypeptides (cED III) and their methods of use
WO2008152652A2 (fr) 2007-06-12 2008-12-18 International Centre For Genetic Engineering And Biotechnology Nouveau vaccin contre le virus de la dengue dirigé contre une protéine tétravalente à base de domaine iii de l'enveloppe
EP2358733B1 (fr) 2008-11-17 2015-07-08 Inovio Pharmaceuticals, Inc. Antigènes qui induisent une réponse immunitaire contre les flavivirus et procédés d' utilisation de ceux-ci
BRPI0904020B8 (pt) 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
WO2011146933A2 (fr) 2010-05-21 2011-11-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Séquences universelles du virus de la dengue et procédés d'utilisation
WO2012045063A2 (fr) 2010-10-01 2012-04-05 University Of Rochester Vaccin contre le flavivirus du domaine iii

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234951A1 (en) * 2001-07-16 2004-11-25 Lisset Hermida Cruz Chimeric chains that coding for proteins that induce effects directed against viruses
WO2009099716A1 (fr) * 2008-01-11 2009-08-13 Vgx Pharmaceuticals, Inc. Nouveaux vaccins contre plusieurs sous-types du virus de la dengue
WO2011115583A1 (fr) * 2010-03-19 2011-09-22 National University Of Singapore Nouvelle plate-forme d'identification d'antigènes de vaccins par particule semblable à un rétrovirus (vlp)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEN YAPING ET AL: "Demonstration of binding of dengue virus envelope protein to target cells", JOURNAL OF VIROLOGY, vol. 70, no. 12, 1996, pages 8765 - 8772, XP002734187, ISSN: 0022-538X *
LI G ET AL: "Comparison of immune responses against foot-and-mouth disease virus induced by fusion proteins using the swine IgG heavy chain constant region or beta-galactosidase as a carrier of immunogenic epitopes", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 3281-3, 5-12, 17, 18, 20-22, no. 2, 25 October 2004 (2004-10-25), pages 274 - 281, XP004581380, ISSN: 0042-6822, DOI: 10.1016/J.VIROL.2004.07.025 *
PURDY D E ET AL: "Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 333, no. 2, 15 March 2005 (2005-03-15), pages 239 - 250, XP004757140, ISSN: 0042-6822, DOI: 10.1016/J.VIROL.2004.12.036 *
SARAH MURRELL ET AL: "Review of dengue virus and the development of a vaccine", BIOTECHNOLOGY ADVANCES, ELSEVIER PUBLISHING, BARKING, GB, vol. 29, no. 2, 29 November 2010 (2010-11-29), pages 239 - 247, XP028136136, ISSN: 0734-9750, [retrieved on 20101210], DOI: 10.1016/J.BIOTECHADV.2010.11.008 *
STAROPOLI I ET AL: "Dengue virus envelope glycoprotein can be secreted from insect cells as a fusion with the maltose-binding protein", JOURNAL OF VIROLOGICAL METHODS, vol. 56, no. 2, 1996, pages 179 - 189, XP002716233, ISSN: 0166-0934 *

Also Published As

Publication number Publication date
ITRM20130458A1 (it) 2015-02-05
WO2015019253A2 (fr) 2015-02-12

Similar Documents

Publication Publication Date Title
MX363533B (es) Proteínas de fusión que comprenden partes de unión a pdgf y vegf y métodos de uso de las mismas.
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
MX2020003260A (es) Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso.
MX2015011408A (es) Antagonistas de il-33 y usos de estos.
WO2015109124A3 (fr) Agents immunomodulateurs
CA2924268C (fr) Anticorps anti-alpha-synucleine et leurs methodes d'utilisation
MX374811B (es) Anticuerpos anti-tau y métodos de uso.
UA112416C2 (uk) Антитіло до fap і способи його застосування
NZ628206A (en) Virus like particle composition
WO2011032161A3 (fr) Vaccins dirigés contre les cellules de langerhans
HK1207654A1 (en) Modified antibody regions and uses thereof
WO2015018528A8 (fr) Modulokines basées sur le domaine "sushi" de l'il-15 et de il-15raplha
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
MX387324B (es) Variantes de regiones fc de igg1 de humano y usos de las mismas.
MX375441B (es) Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor.
WO2015063611A3 (fr) Variants d'albumine et utilisations de ceux-ci
MY170720A (en) Antibody formulations
WO2014184545A3 (fr) Anticorps
MX372950B (es) Anticuerpos.
WO2015021058A3 (fr) Protéines produites par génie génétique avec site de clivage par les protéases
NZ631110A (en) Marker vaccine
WO2014150748A3 (fr) Domaines cd4 humains uniques stabilisés et protéines de fusion
MY188100A (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
MX2020001223A (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas.
HK1207960A1 (en) Human antibodies that bind human tnf-alpha and methods of preparing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14752430

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14752430

Country of ref document: EP

Kind code of ref document: A2